之 中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行 A 股股票 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 声 明 本保荐人及保荐代表人根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发 行上市保荐业务管理办法》、《上市公司证券发行注册管理办法》（以下简称"《注 册管理办法》"）等有关法律、行政法规和中国证券监督管理委员会、深圳证券 交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律 规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书中如无特别说明，相关用语与《海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》中的含义相同。 3-3-1 二〇二五年八月 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 2、主要产品 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 一、发行人基本情况 （一）发行人基本情况 | 公司名称： | 海思科医药集团股份有限公司 | ...

1 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日收到深圳证券交易所（以下简称"深交所"）出具的《关于 海思科医药集团股份有限公司申请向特定对象发行股票的审核问询 函》（审核函〔2025〕120027 号）。深交所发行上市审核机构对公司 向特定对象发行股票的申请文件进行了审核，并形成了审核问询问题。 公司收到审核问询函后，会同相关中介机构对审核问询函所列问 题进行逐项回复和说明，同时对募集说明书等申请文件进行补充和更 新，具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的相 关文件。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得 中国证券监督管理委员会（以下简称"中国证监会"）同意注册后方 可实施，最终是否能通过深交所审核，并获得中国证监会同意注册的 决定及其时间尚存在不确定性。 公司将根据该事项进展情况，按照有关规定和要求及时履行信息 披露义务，敬请广大投资者注意投资风险。 证券代码：002653 证券简称：海思科 公告编号：2025-090 ...

证券简称：海思科 证券代码：002653.SZ 关于海思科医药集团股份有限公司 申请向特定对象发行股票的审核问询函 之回复报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年八月 深圳证券交易所： 贵所《关于海思科医药集团股份有限公司申请向特定对象发行股票的审核问询函》 （审核函〔2025〕120027 号）（以下简称"问询函"）已收悉。海思科医药集团股份 有限公司（以下简称"海思科"、"发行人"或"公司"）会同中信证券股份有限公司 （以下简称"保荐人"）、北京市中伦律师事务所和信永中和会计师事务所（特殊普通 合伙）就问询函所提问题进行了逐项落实并回复，同时按照要求对《海思科医药集团股 份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》（以下简称"募集说明书"） 进行了修订和补充，现回复如下，请贵所予以审核。 说明： 一、如无特别说明，本回复报告中的简称与募集说明书中的简称具有相同的含义。 | 黑体： | 问询函所列问题 | | --- | --- | | 宋体： | 对问询函所列问题的回复 | | 楷体： | 对募集说明书的引用 | | 楷体加粗： ...

Core Viewpoint - The innovative drug concept stocks have shown strong performance recently, driven by favorable policy developments and market dynamics [1][4][5]. Group 1: Market Performance - Innovative drug stocks surged, with Shouyao Holdings hitting a 20% limit up and Haishike also reaching the limit, alongside significant gains from companies like WuXi AppTec and MediSino [1][5]. - Since the start of the current market rally on April 8, the innovative drug sector has seen an overall increase of nearly 60%, with individual stocks like Shutai Shen rising nearly 7 times and Guangsheng Tang over 4 times [5][6]. Group 2: Policy Developments - The National Medical Insurance Administration (NMI) announced that 534 drugs passed the preliminary review for the 2025 National Medical Insurance Drug List, a significant increase from 2024 [4][6]. - A new commercial insurance innovative drug list was established, with 121 drugs approved, indicating a shift towards integrating commercial health insurance with basic medical insurance [6][7]. - The NMI's recent meetings emphasized support for genuine innovation in the pharmaceutical sector, aiming to enhance the quality of drugs and medical devices while rejecting subpar innovations [7][8]. Group 3: Industry Outlook - Analysts are optimistic about the investment opportunities within the pharmaceutical industry, driven by supportive policies and the potential for market recovery in the second half of 2025 [8][9]. - The total market size for innovative drugs in China is estimated to be between 200 billion and 300 billion, with significant growth potential as the country becomes a global R&D hub for innovative drugs [9]. - The policy environment remains favorable for innovative drugs, with major pharmaceutical companies gradually clearing risks associated with drug procurement, paving the way for competitive innovative drug pipelines [9].

Group 1 - The A-share market is experiencing a surge in the pharmaceutical sector, particularly in innovative drugs, with Hai Si Ke reaching its daily limit and Di Zhe Pharmaceutical rising over 8% [1] - The National Healthcare Security Administration has announced the preliminary review of 121 drug names for inclusion in the commercial insurance innovative drug directory, including high-priced CAR-T cancer drugs [1] - The medical sector is seeing a rebound driven by CXO, with the largest medical ETF (512170) hitting a 1.9% increase, and major stocks like Zhaoyan New Drug rising over 8% [3] Group 2 - A new action plan for the high-quality development of "Artificial Intelligence + Healthcare" in Zhejiang Province has been released, focusing on creating multimodal medical industry models and specialized healthcare models [5] - Recent institutional insights suggest that the pharmaceutical sector, led by innovative drugs, is viewed positively for long-term investment, while medical devices are also gaining attention [5] - The largest medical ETF (512170) focuses on medical devices (52%) and medical services (40%), with a strong correlation to AI healthcare, covering six leading CXO stocks [6]

券商科创债今年来发行规模超过400亿元。头部券商专项支持科技创新领域的力度不断加大。申万宏源、中原证券等券商相继获批债券发行额度。7月A股新 开户196.36万户，同比增长70.5%，环比增长19.27%。截至7月末，今年以来A股累计新开1456.13万户。新增开户数据反映出市场活跃度的提升，为券商业务 发展提供支撑。 创新药概念股再度活跃获政策支持 8月13日，A股市场呈现震荡上行态势。创业板指数表现突出，半日涨幅达到2.81%。沪指突破2024年10月8日高点，创下2021年12月17日以来新高。沪深两 市半日成交额达1.32万亿元，较上个交易日放量1181亿元。券商股盘中出现异动拉升，创新药概念股同步走强，为市场注入新的活力。 券商板块异动拉升显现资金青睐 券商股在盘中表现活跃，国盛金控连续两个交易日涨停。证券板块主力资金净流入28.45亿元，位居各行业板块资金流入榜首位。东方财富全天成交额达 110.44亿元，居全市场第一位。金融科技方向上，中科金财、同花顺、大智慧等个股领涨。 市场上涨期间，券商板块受到资金追捧。背后体现的是"卖斧子"的投资逻辑。过去券商主要依靠佣金收入，现在这把"斧子"的载体正转向 ...

Group 1 - The innovative drug concept is experiencing a rebound, with companies like Haikang Science nearing a trading limit and reaching historical highs in stock prices [1] - Several companies, including Shouyao Holdings, Zhaoyan New Drug, Medisi, Changshan Pharmaceutical, Kailaiying, and Dizhe Pharmaceutical, have seen stock price increases of over 5% [1] - On August 12, the National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance catalog and commercial insurance innovative drug catalog, with 534 drugs passing the basic medical insurance catalog review and 121 drug generic names passing the commercial insurance innovative drug catalog review [1] Group 2 - High-priced innovative drugs, including the CAR-T cancer treatment priced in the millions, are pushing for inclusion in the commercial insurance innovative drug catalog, seeking new payment avenues for innovative drugs [1]

Group 1 - The core viewpoint is that the expectation of a Federal Reserve interest rate cut is boosting sentiment in the pharmaceutical sector, with the Medical Innovation ETF (516820.SH) rising by 1.04% [1] - Key stocks such as Haisco (002653), Baili Tianheng (688506), and Kanghong Pharmaceutical (002773) saw significant increases of 4.86%, 3.97%, and 3.91% respectively [1] - The U.S. July core CPI rose by 0.3%, slightly exceeding expectations, while inflation for tariff-sensitive goods remained moderate, reinforcing the expectation of a 25 basis point rate cut in September [1] Group 2 - Longjiang Securities noted that despite the typical vacation period for overseas pharmaceutical executives in July and August, there has been a notable acceleration in overseas expansion, with Chinese innovative drugs reaching $30 billion in exports in just one and a half months [2] - The acceleration in overseas expansion is attributed to pressures in the overseas industry and an increase in the "new" content of domestic innovative drugs [2] - The expectation of a weaker U.S. economy and employment data is likely to accelerate the pace of Federal Reserve rate cuts, enhancing global liquidity and benefiting technology stocks, which may provide an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF (516820) [2]

Group 1 - Huadong Medicine's subsidiary has obtained exclusive commercialization rights for the oral JAK1 inhibitor VC005 from Jiangsu Weikail. The company will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments [1] - VC005 is a novel, potent, and highly selective second-generation oral JAK1 inhibitor currently in clinical development for treating inflammatory and autoimmune diseases, with its fastest clinical progress in Phase III for moderate to severe atopic dermatitis [1] Group 2 - Jidan Bio, as the controlling shareholder of Jingchuan Diagnostics, has faced difficulties in understanding the operational status of Jingchuan due to communication issues, leading to a lawsuit for access to financial data [2] - The final ruling requires Jingchuan Diagnostics to provide company documents and financial reports for review by Jidan Bio and its authorized representatives, highlighting management challenges faced by listed companies over their subsidiaries [2] Group 3 - Zhixiang Jintai announced the resignation of two core technical personnel, with one leaving for personal development and the other due to work adjustments, while a new core technical member has been appointed [3] - The biotech industry relies heavily on core technical teams, and while personnel changes are common, the focus should be on the new members' professional backgrounds and alignment with the company's strategy [3] Group 4 - Haisike's innovative drug HSK47977 has received approval for clinical trials, targeting BCL6 protein to inhibit tumor cell development, specifically for non-Hodgkin lymphoma treatment [4] - HSK47977 is a potential first-in-class product with strong anti-tumor activity and selectivity, showing promising results in preclinical studies [4] Group 5 - Zhengda Tianqing has had two class 1 new cancer drugs accepted for clinical trials in China, marking a significant expansion in its oncology pipeline [5][6] - The drugs include a Bcl-xL protein degradation-targeting chimeric compound and a highly selective PARP1 inhibitor, both aimed at treating malignant tumors [5]

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown significant performance with a recent net value of 4.5530 CNY, despite a slight decline of 1.73% [1] Performance Summary - The fund's one-month return is 12.81%, ranking 628 out of 4566 in its category [1] - Over the past six months, the fund has achieved a return of 48.74%, ranking 108 out of 4413 [1] - Year-to-date, the fund's return stands at 49.47%, with a ranking of 158 out of 4375 [1] Holdings Summary - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14%, with the following key positions: - Heng Rui Medicine: 7.39% - Rejing Biology: 7.00% - Xinlitai: 6.73% - BeiGene-U: 6.47% - Haizhi Science: 6.00% - Nocren Health-U: 5.21% - Yipinhong: 5.08% - Kelun Pharmaceutical: 5.07% - Shutaishen: 5.05% - Baili Tianheng: 4.14% [1] Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]